Rosetta Genomics Ltd. To Host Business Update Conference Call On September 18, 2014

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - September 10, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Wednesday, September 17, 2014, the Company will file financial results for the six months ended June 30, 2014 on Form 6-K with the U.S. Securities and Exchange Commission (“SEC”). The Form 6-K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6-K will be available at www.sec.gov and at www.rosettagenomics.com.

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Thursday, September 18, 2014 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to provide an update on the Company’s business and respond to questions.

Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 2341327. The call is also being webcast, and can be accessed on the investor relations section of the Company’s Web site at www.rosettagenomics.com and also at www.streetevents.com.

A telephone replay will be available through September 24, 2014 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 2341327. The webcast will be available for 30 days following the completion of the call.

About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta’s assays are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to Rosetta’s Cancer Origin Test, Rosetta’s plans or prospects, the timing regarding Rosetta’s filling its financial statement for the first six months of 2014 and Rosetta developing or commercializing molecular diagnostic assays, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.